{"calculatePct":false,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"8"},{"groupId":"OG001","value":"0"},{"groupId":"OG002","value":"11"},{"groupId":"OG003","value":"0"},{"groupId":"OG004","value":"12"},{"groupId":"OG005","value":"1"},{"groupId":"OG006","value":"3"},{"groupId":"OG007","value":"2"},{"groupId":"OG008","value":"7"},{"groupId":"OG009","value":"14"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"18"},{"groupId":"OG001","value":"12"},{"groupId":"OG002","value":"20"},{"groupId":"OG003","value":"5"},{"groupId":"OG004","value":"26"},{"groupId":"OG005","value":"3"},{"groupId":"OG006","value":"10"},{"groupId":"OG007","value":"11"},{"groupId":"OG008","value":"13"},{"groupId":"OG009","value":"28"}],"units":"Participants"}],"description":"Immune-related CBR is defined as the percentage of patients achieving a irCR or irPR, or irSD ≥4 months based on irRECIST criteria","groups":[{"description":"MK-3475: 200 mg of MK-3475 administered intravenously on Day 1 of every 21-day cycle","id":"OG000","title":"Cohort 1: Squamous Cell Carcinoma of the Skin"},{"description":"MK-3475: 200 mg of MK-3475 administered intravenously on Day 1 of every 21-day cycle","id":"OG001","title":"Cohort 2: Small Cell Malignancies of Nonpulmonary Origin"},{"description":"MK-3475: 200 mg of MK-3475 administered intravenously on Day 1 of every 21-day cycle","id":"OG002","title":"Cohort 3: Adrenocortical Carcinoma"},{"description":"MK-3475: 200 mg of MK-3475 administered intravenously on Day 1 of every 21-day cycle","id":"OG003","title":"Cohort 4: Medullary Renal Cell Carcinoma"},{"description":"MK-3475: 200 mg of MK-3475 administered intravenously on Day 1 of every 21-day cycle","id":"OG004","title":"Cohort 5: Carcinoma of Unknown Primary"},{"description":"MK-3475: 200 mg of MK-3475 administered intravenously on Day 1 of every 21-day cycle","id":"OG005","title":"Cohort 6: Penile Carcinoma"},{"description":"MK-3475: 200 mg of MK-3475 administered intravenously on Day 1 of every 21-day cycle","id":"OG006","title":"Cohort 7: Vascular Sarcoma"},{"description":"MK-3475: 200 mg of MK-3475 administered intravenously on Day 1 of every 21-day cycle","id":"OG007","title":"Cohort 8: Germ Cell Tumor"},{"description":"MK-3475: 200 mg of MK-3475 administered intravenously on Day 1 of every 21-day cycle","id":"OG008","title":"Cohort 9: Paraganglioma-pheochromocytoma"},{"description":"MK-3475: 200 mg of MK-3475 administered intravenously on Day 1 of every 21-day cycle","id":"OG009","title":"Cohort 10: Other Rare Tumor Histologies"}],"paramType":"COUNT_OF_PARTICIPANTS","populationDescription":"All patients who have received at least 1 dose of study medication with at least one adequate on-study tumor assessment were included in the efficacy analysis. If a patient discontinued the study before the first radiological assessment due to progression of disease, either radiological or clinical, they were considered evaluable and were included in the efficacy analysis. One patient enrolled in the ACC cohort was excluded from the study due to change in the diagnosis.","reportingStatus":"POSTED","timeFrame":"First day of administration of study medication through 30 days following last dose, an average of 4 years.","title":"Immune-related Clinical Benefit Rate (CBR) Using irRECIST","type":"SECONDARY","unitOfMeasure":"Participants"}